Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma-Reference-Cited by-同舟云学术

Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma

Published:2015-11 Issue:11 Volume:106 Page:1561-1567
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Matsue Kosei¹,Iwasaki Hiromi²,Chou Takaaki³,Tobinai Kensei⁴,Sunami Kazutaka⁵,Ogawa Yoshiaki⁶,Kurihara Mari⁷,Midorikawa Shuichi⁷,Zaki Mohamed⁸,Doerr Thomas⁸,Iida Shinsuke⁹

Affiliation:

1. Division of Hematology/Oncology Department of Medicine Kameda Medical Center KamogawaJapan

2. Center for Cellular and Molecular Medicine Kyushu University Hospital FukuokaJapan

3. Department of Internal Medicine Niigata Cancer Center Hospital NiigataJapan

4. Department of Hematology National Cancer Center Hospital TokyoJapan

5. Department of Hematology National Hospital Organization Okayama Medical Center OkayamaJapan

6. Department of Hematology/Oncology Tokai University School of Medicine IseharaJapan

7. Celgene KK Tokyo Japan

8. Celgene Corporation Summit New Jersey USA

9. Department of Hematology and Oncology Nagoya City University Graduate School of Medical Sciences Nagoya Japan

Funder

Celgene

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.12772

Reference22 articles.

1. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

2. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

3. Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma

4. The anti‐proliferative effect of lenalidomide on MM cells in vitro is ameliorated by prior exposure to pomalidomide, an agent with activity against lenalidomide resistant MM cells;Adams M;Blood,2009

5. Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lenalidomide and pomalidomide modulate hematopoietic cell expansion and differentiation in the presence of MSC;International Journal of Hematology;2024-07-12

2. Determination of the Physical and Chemical Properties of Pomalidomide (Form A);Pharmaceutical Chemistry Journal;2022-12

3. A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma;Scientific Reports;2021-09-29

4. A sensitive and validated LC-MS/MS method for high-throughput determination of pomalidomide in human plasma and pharmacokinetic studies;Chinese Chemical Letters;2021-07

5. Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma (KEYNOTE-183): subgroup analysis in Japanese patients;International Journal of Hematology;2021-04-15